January 30, 2017 07:57 AM EST

FibroGen, AstraZeneca ready China application as anemia drug scores in two pivotal studies

John Carroll

Editor & Founder

Fibrogen $FGEN and AstraZeneca $AZN took a big step toward completing their new drug application in China for the anemia drug roxadustat after hitting the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FibroGen, AstraZeneca ready China application as anemia drug scores in two pivotal studies

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus

Fi­bro­Gen, As­traZeneca ready Chi­na ap­pli­ca­tion as ane­mia drug scores in two piv­otal stud­ies

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FibroGen, AstraZeneca ready China application as anemia drug scores in two pivotal studies

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus